Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Sherko Kuemmel"'
Autor:
Henriette Christgen, Laura Bollmann, Mieke Raap, Rachel Wuerstlein, Bahriye Aktas, Ronald E. Kates, Ulrike Nitz, Ulrich Lehmann, Monika Graeser, Oleg Gluz, Michael Braun, Hans Kreipe, Sherko Kuemmel, Claudia Schumacher, Matthias Christgen, Malte Gronewold, Stephan Bartels, Nadia Harbeck, Eva-Maria Grischke, Christine Eulenburg, Isabel Grote, Kerstin Luedtke-Heckenkamp, Leonie Kandt
Publikováno v:
Cancer Medicine, Vol 10, Iss 23, Pp 8581-8594 (2021)
Cancer Medicine
Cancer Medicine
Background Whereas the genomic landscape of endocrine‐resistant breast cancer has been intensely characterized in previously treated cases with local or distant recurrence, comparably little is known about genomic alterations conveying primary non
Autor:
Doris Augustin, Rachel Wuerstlein, Henriette Christgen, Toralf Reimer, Nadia Harbeck, Bahriye Aktas, Ronald E. Kates, Benno Nuding, Marianne Just, Petra Krabisch, Wolfram Malter, Oleg Gluz, Monika Graeser, Michael R. Clemens, Sherko Kuemmel, Andrea Stefek, Matthias Christgen, Frederick L. Baehner, Mieke Raap, Hans Kreipe, Ulrike Nitz
Publikováno v:
Cancer. 126:4847-4858
BACKGROUND Invasive lobular breast cancer (BC) is the second most common BC subtype. Prognostic parameters (tumor classification, lymph node status, histologic grade, Oncotype DX recurrence score [RS], progesterone receptor status, and Ki67 index) we
Autor:
Stephanie Schneider, Caroline Vogt, Mattea Reinisch, Johanna Frindte, Vincenzo Bluni, Sonia Prader, Gudrun Gebers, Sherko Kuemmel, Mareike Bommert, Alexander Traut, Elisabeth Breit, Philipp Harter, Andreas du Bois, Athina Kostara, Beyhan Ataseven, Florian Heitz
Publikováno v:
Supportive Care in Cancer. 28:3605-3615
Due to advances in anticancer treatment and supportive care, patients increasingly complained about nonphysical side effects of chemotherapy and targeted therapy in recent years. Therefore, continuous assessment of side effects and patients’ percep
Autor:
Heiko Graf, Bernhard Volz, Matthias W. Beckmann, Bernhard Martin, Christian M. Bayer, Achim Rody, Alexander Fridman, Christoph Thomssen, CB Walter, Andreas D. Hartkopf, Tanja Fehm, Felix Heindl, Rachel Wuerstlein, Volker Schulz, Sara Y. Brucker, Brigitte Rack, Peter A. Fasching, Christian R. Loehberg, Dieter Steinfeld-Birg, Tobias Brodkorb, Hans-Christian Kolberg, Wolfram Malter, Katrin Almstedt, Carolin C. Hack, Lothar Häberle, G. Baake, Petra Krabisch, Nicolai Maass, Sherko Kuemmel, Volker Pelzer, Christoph Lindner, Paul Gass, C. Wolf, Michael Weigel, A. Kohls, Michael P. Lux, Claudia Rauh, C Brucker, Oliver Hoffmann, Wolfgang Janni, Naiba Nabieva, Nadia Harbeck, Alexander Hein, G. Fischer
Publikováno v:
International Journal of Cancer. 145:2114-2121
One of the most common adverse events (AEs) occurring during treatment with aromatase inhibitors (AIs) is musculoskeletal pain. The aim of our study was to analyze the influence of preexisting muscle/limb pain and joint pain on the development of AI-
Autor:
Wolfram Malter, Marion van Mackelenbergh, Mattea Reinisch, Sebastian Wojcinski, Jens-Uwe Blohmer, Marc Thill, Paul Bach, K. Friedrichs, Sherko Kuemmel, Joerg Heil, Nina Ditsch, Achim Rody, Inga Bekes, R Große, Michael Golatta, MM Karsten, Hans-Peter Sinn, Toralf Reimer, André Pfob, John Hackmann, Geraldine Rauch, Benedikt Schaefgen, Stefan Paepke, Markus Hahn, Responder Investigators, Sylvie Joos, Bettina C Thomas
Publikováno v:
Annals of surgery. 275(3)
OBJECTIVE We evaluated the ability of minimally invasive, image-guided vacuum-assisted biopsy (VAB) to reliably diagnose a pathologic complete response in the breast (pCR-B). SUMMARY BACKGROUND DATA Neoadjuvant systemic treatment (NST) elicits a path
Autor:
Tineke J. Smilde, Miguel Gil-Gil, A. Lesur, C. Poncet, Etienne Brain, Susan J. Knox, Franchette W P J van den Berkmortel, Giuseppe Viale, Isabel T. Rubio, Zaman Khalil, Gabriele Zoppoli, Alastair M. Thompson, Jean-Yves Pierga, Florentine Hilbers, Laura J. van't Veer, Sherko Kuemmel, Suzette Delaloge, Aleksandra Dudek-Peric, Konstantinos Tryfonidis, Saskia Litière, Emiel J. Th. Rutgers, Patricia Gomez, Georg Kunz, Peter Vuylsteke, Jan Bogaerts, Fatima Cardoso, Mahasti Saghatchian, Peter M. Ravdin, Martine Piccart
Publikováno v:
J Clin Oncol
Journal of clinical oncology, Vol. 38, no. 11, p. 1186-1197 (2020)
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 11
Journal of clinical oncology, Vol. 38, no. 11, p. 1186-1197 (2020)
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 11
PURPOSE MINDACT demonstrated that 46% of patients with early breast cancer at high clinical but low genomic risk on the basis of MammaPrint may safely avoid adjuvant chemotherapy. A second random assignment (R-C) compared docetaxel-capecitabine with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2f811ce3d449b2b5742e51d01a89a56
https://europepmc.org/articles/PMC7840116/
https://europepmc.org/articles/PMC7840116/
Autor:
Keun Seok Lee, Louis W.C. Chow, Joohyuk Sohn, Debu Tripathy, Seock-Ah Im, Saúl Campos-Gómez, Mei Ching Liu, Paul Wheatley-Price, Aditya Bardia, K Govind Babu, Yen-Shen Lu, Rafael Villanueva Vazquez, Fabio Franke, Sara A. Hurvitz, Samit Hirawat, C. Germa, Gary Carlson, Kyung Hae Jung, I Diaz-Padilla, Young-Hyuck Im, Sherko Kuemmel, Nadia Harbeck, Gareth Hughes, Nagi S. El-Saghir, Michelino De Laurentiis, Marco Colleoni
Publikováno v:
The Lancet Oncology. 19:904-915
Background: In MONALEESA-2, ribociclib plus letrozole showed improved progression-free survival compared with letrozole alone as first-line treatment for postmenopausal patients with hormone receptor (HR)-positive, HER2-negative, advanced breast canc
Autor:
A. Kohls, Hans-Peter Fischer, Ronald E. Kates, Matthias Christgen, Michael Braun, T. Reimer, Hans Heinrich Kreipe, Nadia Harbeck, Jochem Potenberg, Katja Krauss, E-M. Grischke, Andrea Stefek, Helmut Forstbauer, O Gluz, Doris Augustin, Ulrike Nitz, Claudia Schumacher, Johannes Schumacher, Cornelia Liedtke, Sherko Kuemmel, Rachel Wuerstlein
Publikováno v:
Annals of Oncology. 28:2768-2772
Response rates in HER2-overexpressing EBC treated with neoadjuvant chemotherapy and trastuzumab (T) have been improved by addition of pertuzumab (P). The prospective, phase II, neoadjuvant WSG-ADAPT HER2+/HR- trial assessed whether patients with stro
Autor:
Katarzyna Jozwiak, Helmut Forstbauer, Valery Volk, Eva-Maria Grischke, Claudia Schumacher, Christoph Uleer, Hans Kreipe, Michael Hauptmann, Oleg Gluz, Rachel Wuerstlein, John Hackmann, Michael Braun, Bahriye Aktas, Ulrike Nitz, Monika Graeser, Ronald E. Kates, Nadia Harbeck, Sherko Kuemmel, Cornelia Kolberg-Liedtke, Matthias Christgen, Friedrich Feuerhake, Mathias Warm
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundThe association of early changes in the immune infiltrate during neoadjuvant chemotherapy (NACT) with pathological complete response (pCR) in triple-negative breast cancer (TNBC) remains unexplored.MethodsMultiplexed immunohistochemistry wa
Autor:
Ulrike Nitz, Oleg Gluz, Matthias Christgen, Ronald E. Kates, Michael Clemens, Wolfram Malter, Benno Nuding, Bahriye Aktas, Sherko Kuemmel, Toralf Reimer, Andrea Stefek, Fatemeh Lorenz-Salehi, Petra Krabisch, Marianne Just, Doris Augustin, Cornelia Liedtke, Calvin Chao, Steven Shak, Rachel Wuerstlein, Hans H. Kreipe, Nadia Harbeck
Publikováno v:
Breast Cancer Research and Treatment
Background The prospective phase 3 PlanB trial used the Oncotype DX® Recurrence Score® (RS) to define a genomically low-risk subset of clinically high-risk pN0-1 early breast cancer (EBC) patients for treatment with adjuvant endocrine therapy (ET)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b4a4e0c7f424a0aadc5353df8d3ace5
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85059841249
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85059841249